89bio, Inc.

Biotechnology • Healthcare • San Francisco, CA, United States • ETNB (NGM)

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.

415 432 9270 655 Montgomery Street, San Francisco, CA 94111, United States

Stock Performance (90 Days)

Data through Oct 30, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal - Yahoo Finance

Yahoo Finance • Sep 30

Why Did 89bio Stock Nearly Double In Value Today? - Stocktwits

Stocktwits • Sep 18

After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks - Fierce Biotech

Fierce Biotech • Oct 2

Roche to pay $2.4B to acquire 89bio and its MASH hopeful pegozafermin - FirstWord Pharma

FirstWord Pharma • Sep 18

Roche to acquire liver drug developer 89bio for up to $3.5 billion - Reuters

Reuters • Sep 18

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has 89bio, Inc. had layoffs?

No layoff events have been recorded for 89bio, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does 89bio, Inc. have?

89bio, Inc. has approximately 93 employees.

What industry is 89bio, Inc. in?

89bio, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is 89bio, Inc. a publicly traded company?

Yes, 89bio, Inc. is publicly traded under the ticker symbol ETNB on the NGM. The company has a market capitalization of approximately $2.20 billion.

Where is 89bio, Inc. headquartered?

89bio, Inc. is headquartered in San Francisco, CA, United States at 655 Montgomery Street, San Francisco, CA 94111, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.